Periodic Reporting for period 1 - UbiHealth (Transforming Molecular Diagnostics through NanoTechnology)
Reporting period: 2024-12-01 to 2025-11-30
Project Summary
Altratech introduce a completely new method of molecular detection. This is a first-of-kind, multianalyte DNA, RNA, antibody and antigen diagnostic. It delivers concurrent serology and nucleic acid detection. The technology is compliant with the challenging demands of WHO REASSURED criteria, especially in providing a commercially viable diagnostic tool for the developing world.
The innovation is in the process of being productised by our sub-contractor The Cambridge Design Partnership (UK) into a fully automated, portable, stand-alone instrument for Point of Care and Point of Need. It will not require medically qualified personnel to operate. This innovation provides substantial advantages over existing, more complex, expensive and less portable Point of Care systems for the management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.
The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.
Altratech introduce a completely new method of molecular detection. This is a first-of-kind, multianalyte DNA, RNA, antibody and antigen diagnostic. It delivers concurrent serology and nucleic acid detection. The technology is compliant with the challenging demands of WHO REASSURED criteria, especially in providing a commercially viable diagnostic tool for the developing world.
The innovation is in the process of being productised by our sub-contractor The Cambridge Design Partnership (UK) into a fully automated, portable, stand-alone instrument for Point of Care and Point of Need. It will not require medically qualified personnel to operate. This innovation provides substantial advantages over existing, more complex, expensive and less portable Point of Care systems for the management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.
The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.
•Isothermal (Recombinase Polymerase Amplification) protocol developed, detecting down to 1000 copies/mL from whole blood, and four other concentrations from whole blood and plasma.
•A filtration system provided a practical method of plasma separation and using this workflow, reliably detected HIV RNA at 1,000 copies/mL on the Altratech CMOS chip cartridge.
•A filtration system provided a practical method of plasma separation and using this workflow, reliably detected HIV RNA at 1,000 copies/mL on the Altratech CMOS chip cartridge.
Altratech Detection Cartridge showed greater sensitivity than gold-standard optical detection at very low copy numbers (≥ 50 copies/mL).